So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

Euronext posts strong results, trades at a discount to peers, and gains from equity rotation, SaaS growth, and new products.

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

By Michael Levenson 23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Several hundred job cuts will affect Bay Area workers in the tech, biotech, energy and school sectors, according to official state filings. Bay Area bounces back with job gains, with warnings ...

You can reach Jason on Signal at JasonMast.05. Prime Medicine, a biotech whose wild ambitions for a powerful gene editing technology sank as the biotech market slumped, announced Monday it is ...

The RBA cut its cash rate by 25 bps to 3.85%, citing moderating inflation and heightened global uncertainty as key reasons ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...